Biogen Inc

NASDAQ:BIIB  
211.97
+0.59 (+0.28%)
Products, Strategic Combinations

Biogen And Alectos Therapeutics Announce License And Collaboration Agreement For Al01811

Published: 06/06/2022 12:42 GMT
Biogen Inc (BIIB) - Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for Al01811, a Novel Gba2 Inhibitor for the Potential Treatment of Parkinson’s Disease.
Biogen Inc - Alectos to Receive a $15 Million Upfront Payment.
Biogen Inc - Alectos is Eligible to Receive Potential Future Development and Commercial Milestone Payments.
Biogen Inc - Alectos Eligible to Receive Up to $77.5 Million in Potential Development Payments.
Biogen Inc - Alectos is Eligible to Receive Up to $630 Million in Potential Commercial Payments Should Collaboration Achieve Certain Milestones.
Biogen Inc - Alectos is Also Eligible to Receive Tiered Royalties in High-single-digits to Mid-teens.
Biogen Inc - Moving Forward, Both Companies Will Collaborate on Preclinical Activities for Al01811.
Biogen -once Al01811 Advanced to Clinic, Co to Assume Sole Responsibility for All Development, Regulatory, Manufacturing, Commercial Activities, Costs.